REG - BSF Enterprise PLC - Investor Evening

BSF EnterpriseAnnouncement

14/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240314:nRSN8416Ga&default-theme=true

RNS Number : 8416G  BSF Enterprise PLC  14 March 2024

14 March 2024

BSF Enterprise PLC

("BSF" or the "Company")

 

BSF Investor Evening

 

BSF Enterprise would like to welcome current shareholders and interested
investors to an Investor Evening organised by Shard Capital Partners LLP on
Tuesday, 19 March 2024.

 

At the event, a presentation will be delivered by the management of BSF
Enterprise, followed by a Q&A session.

 

Hospitality will be provided.

 

The event will take place at 1790 Bar, St Swithin's Lane, London from 17.30

 

To register your interest in attending, please use the following link:
https://forms.gle/FEmtcZT4mAA1DzS99 (https://forms.gle/FEmtcZT4mAA1DzS99)

 

********************************************

 

Notes to Editors

 

About BSF Enterprise PLC:

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of
biotechnological solutions - using cell-based tissue engineering to help
generate cultured meat, lab-grown leather, as well as human corneas, collagen
growth and skin substitutes, as part of a radical transformation to deliver
sustainable solutions across a variety of sectors.

 

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with
patent-protected IP that is already producing human corneas for testing to
help restore vision to millions of people. Building on this success, it aims
to produce the UK's first high quality leather from its laboratory in
Newcastle, transforming the leather industry towards an ethical and
sustainable practice.

 

BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as well as
through M&A. It aims to develop a suite of technologies that underpins the
development of tissue templating for corneas, meat and leather, and license
out the IP to manufacturers, wholesalers and distributors to help manufacture
the products at scale.

 

 --------------------------------------------------------------------

 BSF Enterprise PLC                                                     Via SEC Newgate below
 Geoff Baker - Executive Director

 Che Connon - CEO & Director

 Shard Capital (Broker)
 Damon Heath                                                            0207 186 9000

 Isabella Pierre                                                        0207 186 9927

 SEC Newgate (Financial Communications)
 Bob Huxford                                                            020 3757 6882

 Elisabeth Cowell                                                       BSF@secnewgate.co.uk

 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFIFFRVEISLIS